

Advancing the Practice of Community Pharmacy



COMPLETED GRANT SYNOPSIS

Developing a model of care for medications for opioid use disorder at community pharmacies

Jennifer Bacci¹, Boris Zhang², Sierra Brackeen¹, Jenny Arnold², Ryan Hansen¹
¹University of Washington School of Pharmacy| Seattle, WA
²Washington State Pharmacy Association| Renton, WA

Objectives

The goal of this study was to adapt existing evidence-based models of care for medications for opioid use disorder (MOUD) access to a new context or care setting, community pharmacies, through pursuit of the following objectives:

- <u>Objective #1</u>: Conduct key informant interviews with pharmacy staff, other opioid use disorder (OUD) providers, and people with lived experience to map how existing models of care for MOUD access match factors that impede or promote OUD treatment in community pharmacies.
- <u>Objective #2</u>: Develop a preliminary resource guide outlining models of care and complementary implementation strategies based on key informant interviews and feedback from an interdisciplinary advisory panel.

Methods

Design

- This study employed qualitative analysis of data collected via key informant interviews from January to May 2024.
- There were 3 groups that were recruited to participate in one, 60-minute virtual key informant interview:
 - Community pharmacy staff This group was comprised of pharmacists and pharmacy technicians practicing at a community pharmacy in Washington State.
 - OUD treatment providers This group consisted of medical professionals and administrators who are involved in providing OUD treatment or overseeing OUD treatment programs in Washington State in care settings other than community pharmacy (e.g., primary care, emergency department, office-based opioid treatment clinic (OBOT)).
 - People with lived experience This group included adults who have previously taken or are currently taking MOUD and reside in Washington State.
- The <u>Practical</u>, <u>Robust Implementation and Sustainability Model (PRISM)</u> and <u>existing evidence-based</u> <u>models of care for access to MOUD in primary care settings</u> were used to guide interview question development and analysis.
- Interview transcripts were analyzed using a rapid content analysis approach.
- A 16-person advisory panel met 3 times during the study to provide insights and feedback on interview guide development, data analysis, and model of care development. The panel included people with lived experience, physicians, community pharmacists, behavioral health pharmacists, public health representatives, and payor representatives.

Study endpoints

- Community pharmacy staff, OUD treatment provider, and people with lived experience perspectives of:
 - o Intervention characteristics, including the drug therapy, education, coordination of care, and psychosocial features that should in included in a community pharmacy-based intervention.
 - Recipients, including the people or patients who would most benefit from a community pharmacy-based intervention and community pharmacies most well suited to offer an MOUD intervention
 - o Implementation and sustainability infrastructure, including the strategies needs to integrate and maintain an MOUD intervention at community pharmacies over the long term
 - External environment or factors outside of a community pharmacy than can influence an intervention's success and sustainability

• Development of a preliminary resource guide outlining a model of care(s) and complementary implementation strategies

Results

- Interviews were conducted with 9 community pharmacy staff (5 pharmacists and 4 pharmacy technicians), 11 OUD treatment providers, and 11 people with lived experience in patients.
- In total, 21 themes were identified, including 8 themes regarding intervention characteristics, 5 themes regarding recipients, 5 themes regarding implementation and sustainability infrastructure, and 3 themes regarding external environment:

PRISM Domains		Model of Care Domains		Themes	
Intervention characteristics		Drug therapy		Medication options	
				2. MOUD initiation	
				3. MOUD monitoring and follow-up	
		Education	For community	4. Clinical knowledge and abilities	
			pharmacy staff	5. Harm reduction and stigma	
			For people with OUD	6. Medication education	
		Coordination of care		7. Increased communication	
		Psychosocial services		8. Referrals	
Recipients	Patients			9. Rural and limited access	
				10. Ease of access/ timeliness	
				11. Patient preference	
	Community pharmacies	armacies		12. Person-centered approach	
				13. Organizational support and	
		Not applicable		infrastructure	
Implementation and sustainability				14. Technology	
infrastructure				15. Physical space	
				16. Scope of practice	
				17. Payment for services	
				18. Marketing/ advertising	
External environment				19. Drug supply	
				20. Cost of medications and care	
				21. Drug use trends in the	
				community	

• Two models of care for MOUD at community pharmacies were developed from the interview themes with input from an interdisciplinary advisory panel:

	Components					
Model	Drug Therapy Education		Coordination of Care	Psychosocial Services		
Low-Barrier Buprenorphine <u>Initiation</u>	Buprenorphine- naloxone	Pharmacy staff education including clinical (e.g., OUD, MOUD) and patient care (e.g., traumainformed care, harm reduction) components	Referral/ warm handoff to primary or specialized care provider for titration and maintenance	Referral to local resources and/or services when appropriate		
		Patient counseling Primary care/ specialized provider education on model of care				

Low-Barrier	Buprenorphine-	Pharmacy staff education	Provided in collaboration	Referral to local
MOUD	naloxone, injectable	including clinical (e.g.,	with a local OBOT, OTP,	resources and/or
<u>Maintenance</u>	naltrexone, and/or	OUD, MOUD) and patient	or clinic	services when
	injectable	care (e.g., trauma-		appropriate
	buprenorphine	informed care, harm		
		reduction) components		
		Patient medication		
		management		

Conclusion

Through key informant interviews with community pharmacy staff, OUD treatment providers, and people with lived experience, we identified 21 themes regarding models of care for MOUD in community pharmacy across intervention characteristics, recipients, implementation and sustainability infrastructure, and external environment. These findings underscore the potential for community pharmacy teams to play a pivotal role in expanding access to MOUD by leveraging their accessibility and reach. They also informed the development of 2 distinct models of care that minimize administrative hurdles to meet people where they are without stigma or discrimination. A preliminary resource guide was developed to provide a foundation for integrating these models of care into community pharmacies. Future work will focus on the implementation and evaluation of these models of care in community pharmacies to ensure their effectiveness and sustainability with the long-term goal of increasing access to MOUD and improving outcomes for people with OUD.